367 related articles for article (PubMed ID: 16881109)
1. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis.
Fiedorczyk M; Klimiuk PA; Sierakowski S; Gindzienska-Sieskiewicz E; Chwiecko J
J Rheumatol; 2006 Aug; 33(8):1523-9. PubMed ID: 16881109
[TBL] [Abstract][Full Text] [Related]
2. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
3. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis.
Klimiuk PA; Fiedorczyk M; Sierakowski S; Chwiecko J
Scand J Rheumatol; 2007; 36(5):345-50. PubMed ID: 17963163
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
5. [Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis].
Fiedorczyk M; Klimiuk PA; Sierakowski S; Domysławska I; Chwiećko J
Przegl Lek; 2005; 62(12):1321-4. PubMed ID: 16786739
[TBL] [Abstract][Full Text] [Related]
6. Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients.
Tchetverikov I; Kraan MC; van El B; Hanemaaijer R; DeGroot J; Huizinga TW
Ann Rheum Dis; 2008 Jan; 67(1):128-30. PubMed ID: 17875551
[TBL] [Abstract][Full Text] [Related]
7. [Correlation between tumor necrosis factor alpha and matrix metalloproteinases levels in serum of patients with rheumatic arthritis].
Klimiuk PA; Sierakowski S; Chwiećko J
Pol Merkur Lekarski; 2003 May; 14(83):410-2. PubMed ID: 12939814
[TBL] [Abstract][Full Text] [Related]
8. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
[TBL] [Abstract][Full Text] [Related]
9. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.
O'Dell JR; Elliott JR; Mallek JA; Mikuls TR; Weaver CA; Glickstein S; Blakely KM; Hausch R; Leff RD
Arthritis Rheum; 2006 Feb; 54(2):621-7. PubMed ID: 16447240
[TBL] [Abstract][Full Text] [Related]
10. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
[TBL] [Abstract][Full Text] [Related]
11. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
Vandooren B; Kruithof E; Yu DT; Rihl M; Gu J; De Rycke L; Van Den Bosch F; Veys EM; De Keyser F; Baeten D
Arthritis Rheum; 2004 Sep; 50(9):2942-53. PubMed ID: 15457463
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
[TBL] [Abstract][Full Text] [Related]
13. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis.
Ishiguro N; Ito T; Obata K; Fujimoto N; Iwata H
J Rheumatol; 1996 Sep; 23(9):1599-604. PubMed ID: 8877931
[TBL] [Abstract][Full Text] [Related]
14. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls.
Laurberg TB; Frystyk J; Ellingsen T; Hansen IT; Jørgensen A; Tarp U; Hetland ML; Hørslev-Petersen K; Hornung N; Poulsen JH; Flyvbjerg A; Stengaard-Pedersen K
J Rheumatol; 2009 Sep; 36(9):1885-91. PubMed ID: 19684150
[TBL] [Abstract][Full Text] [Related]
15. [Serum interleukin 6 (il-6A) concentration correlates with matrix metalloproteinases and their tissue inhibitors in rheumatoid arthritis].
Klimiuk PA; Sierakowski S; Chwiećko J
Pol Arch Med Wewn; 2003 Feb; 109(2):119-23. PubMed ID: 12879774
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases and their tissue inhibitors (TIMPs) in Plasmodium falciparum malaria: serum levels of TIMP-1 are associated with disease severity.
Dietmann A; Helbok R; Lackner P; Issifou S; Lell B; Matsiegui PB; Reindl M; Schmutzhard E; Kremsner PG
J Infect Dis; 2008 Jun; 197(11):1614-20. PubMed ID: 18700258
[TBL] [Abstract][Full Text] [Related]
17. Production of matrix metalloproteinases and their inhibitors in osteoarthritic patients undergoing mud bath therapy.
Bellometti S; Richelmi P; Tassoni T; Bertè F
Int J Clin Pharmacol Res; 2005; 25(2):77-94. PubMed ID: 16060398
[TBL] [Abstract][Full Text] [Related]
18. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis.
Martel-Pelletier J; McCollum R; Fujimoto N; Obata K; Cloutier JM; Pelletier JP
Lab Invest; 1994 Jun; 70(6):807-15. PubMed ID: 8015285
[TBL] [Abstract][Full Text] [Related]
19. Plasma level of CXC-chemokine CXCL12 is increased in rheumatoid arthritis and is independent of disease activity and methotrexate treatment.
Hansen IB; Ellingsen T; Hornung N; Poulsen JH; Lottenburger T; Stengaard-Pedersen K
J Rheumatol; 2006 Sep; 33(9):1754-9. PubMed ID: 16960937
[TBL] [Abstract][Full Text] [Related]
20. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
